Skip to content
Godavari Drugs logo

Godavari Drugs

530317 BSE
Price unavailable

Godavari Drugs (GODAVARI) share price was ₹121.00 at the 28 Oct 2026 close; market capitalisation ₹132 Cr; P/E (TTM) 25.69; sector Healthcare. The share price rose 39.8% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Jun 2026 quarter, revenue rose 17.4% year on year to ₹27.96 Cr and net profit rose 6.7% year on year to ₹1.11 Cr (compared with Jun 2025). Promoters held 40.23% of Godavari Drugs in Sep 2026, unchanged from Jun 2026. Its Tapetide Score is 46/100 (Average) as of 28 Oct 2026.

Close 28 Oct 2026 ₹121.00 +35.38 +41.32% 1Y

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare
Market Cap
₹132 Cr
P/E (TTM)
25.69
EBITDA
₹11.10 Cr
Return on Equity
5.39%
Debt to Equity
1.08
Book Value
₹71.05
EPS (TTM)
₹4.71
52W High
₹144.35
52W Low
₹69.70

Price-based figures as of 28 Oct 2026, 15:30 IST · EPS basis: Standalone · TTM

Peer Comparison

Healthcare › Pharmaceuticals

Sun Pharma
₹1,766.7035.054,23,891 Cr5.070.91%13.79%17.94%61,848 Cr12,117 Cr
Divis Laboratories
₹9,655.0087.632,56,310 Cr15.290.32%15.32%18.96%11,682 Cr2,925 Cr
Torrent Pharmaceuticals
₹4,610.8072.381,75,380 Cr9.550.82%12.16%9.06%17,058 Cr2,156 Cr
Laurus Labs
₹2,187.80108.091,18,210 Cr22.300.09%16.38%19.67%7,323 Cr1,090 Cr
Zydus Life Science
₹1,181.3026.291,17,835 Cr4.350.09%16.99%19.24%28,515 Cr4,593 Cr
Dr Reddys Laboratories
₹1,338.4034.661,11,714 Cr2.880.61%10.87%13.94%34,247 Cr3,184 Cr
Cipla
₹1,365.2032.711,10,289 Cr3.120.96%11.21%14.88%28,589 Cr3,356 Cr
Godavari Drugs (this company)
—25.69132 Cr1.700.00%5.39%7.84%111 Cr4 Cr
Median 8 companies₹1,766.7034.861,18,022 Cr4.710.47%12.98%16.41%22,787 Cr3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

46 Average
Overall score

Data confidence 100/100

Category scores

Quality Average 46
Returns, margins, earnings quality 22% weight
Valuation Poor 36
Cheap vs sector & own history 24% weight
Growth Weak 44
Sales & profit trajectory 9% weight
Financial Health Poor 25
Solvency, leverage, coverage 9% weight
Momentum Good 65
Trend strength, vol-adjusted 12% weight
Ownership Average 51
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Weaknesses

6
  • Though the company is reporting repeated profits, it is not paying out dividend
  • The company has delivered a poor sales growth of -2.91% over past five years.
  • Company has a low return on equity of 9.95% over last 3 years.
  • Company might be capitalizing the interest cost
  • Company has high debtors of 150 days.
  • Promoter holding has decreased over last 3 years: -12.9%

Technical Indicators

Oscillators

Bearish

Bearish
2
Neutral
6
Bullish
1

Overall

Bullish

Bearish
6
Neutral
6
Bullish
7

Moving Averages

Bullish

Bearish
4
Neutral
0
Bullish
6

Growth Rate

Revenue Growth
-6.74% higher than 3Y

change over 1 year

Net Income Growth
-6.82% lower than 3Y

change over 1 year

Cash Flow Change
-93.48%

change over 1 year

EBITDA Margin Change
-6.87%

change over 1 year Operating margin 9.01% · Jun 2026

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
35.42
39.54
43.11
38.64
32.21
26.09
29.55
25.5
23.81
26.65
22.18
33.16
27.96
Expenses
33.17
36.47
39.59
34.17
28.98
23.19
26.97
22.39
20.91
24.65
19.71
30.22
25.44
Operating Profit
2.25
3.07
3.52
4.47
3.23
2.9
2.58
3.11
2.9
2
2.47
2.94
2.52
OPM %
6.35%
7.76%
8.17%
11.57%
10.03%
11.12%
8.73%
12.2%
12.18%
7.5%
11.14%
8.87%
9.01%
Other Income
0.45
0
-0.01
0.08
0.77
0.01
0.1
0.11
0.01
0.64
0.27
0.25
0.15
Interest
1.11
1.3
1.27
1.23
1.44
1.08
1.11
1.11
1
0.91
1.11
0.96
0.9
Depreciation
0.47
0.49
0.5
0.53
0.55
0.58
0.64
0.67
0.6
0.6
0.61
0.61
0.59
PBT
1.12
1.28
1.74
2.79
2.01
1.25
0.93
1.44
1.31
1.13
1.02
1.62
1.18
Tax %
27.68%
32.81%
29.89%
4.66%
18.91%
12.8%
16.13%
38.19%
19.85%
10.62%
25.49%
20.37%
5.93%
Net Profit
0.81
0.86
1.22
2.66
1.63
1.09
0.77
0.89
1.04
1
0.76
1.29
1.11
EPS (₹)
1.08
1.14
1.62
3.53
2.16
1.45
1.02
1.18
1.38
1.33
1.01
1.27
1.1
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
55
71
76
64
84
96
123
161
160
157
113
106
110
Expenses
49
67
70
60
78
90
113
150
150
143
102
95
100
Operating Profit
6
4
5
4
5
6
10
11
10
13
12
10
10
OPM %
11%
6%
7%
6%
7%
6%
8%
7%
6%
8%
10%
10%
9%
Other Income
0
0
1
1
0
0
0
0
1
1
1
1
1
Interest
1
2
3
2
3
3
3
3
4
5
5
4
4
Depreciation
1
1
1
1
1
1
1
2
2
2
2
2
2
PBT
5
2
3
1
2
2
6
7
5
7
6
5
5
Tax %
23%
38%
33%
37%
31%
13%
28%
25%
23%
20%
22%
19%
—
Net Profit
4
1
2
1
1
2
4
5
4
6
4
4
4
EPS (₹)
4.85
1.79
2.4
1.1
1.61
2.66
5.48
6.97
5.03
7.37
5.82
4.04
4.71
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
8
8
8
8
8
8
8
8
8
8
8
10
Reserves
6
7
9
10
11
13
17
22
26
31
36
66
Borrowings
8
16
16
19
22
28
30
23
36
58
64
82
Other Liabilities
13
21
24
27
33
36
36
49
52
38
35
43
Total Liabilities
35
51
56
63
74
84
91
101
121
135
143
200
Fixed Assets
7
9
13
15
15
14
22
26
25
27
33
30
CWIP
0
1
0
1
2
9
1
0
9
18
30
57
Investments
0
0
0
0
0
0
0
0
0
0
0
0
Other Assets
27
41
43
47
57
61
68
75
87
90
81
114
Total Assets
35
51
56
63
74
84
91
101
121
135
143
200
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
-6
-5
5
4
4
6
1
11
13
18
11
1
Investing
0
-2
-3
-3
-2
-7
-1
-5
-9
-13
-20
-26
Financing
6
7
-2
0
-1
0
0
-6
-4
-6
8
37
Net Cash Flow
0
0
0
1
0
0
0
1
1
0
0
12
Free Cash Flow
-6
-7
1
0
1
-1
0
6
4
5
-9
-26
CFO/OP
-101
-101
108
109
73
108
26
110
143
146
105
19
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
87
126
117
152
148
137
134
126
132
138
136
150
Inventory Days
84
67
70
100
93
84
55
28
57
62
125
217
Days Payable
79
108
124
171
171
144
112
121
132
96
128
163
Cash Conversion Cycle
92
85
63
81
70
78
78
33
58
105
133
204
Working Capital Days
63
44
40
47
38
31
46
32
23
9
11
42
ROCE %
32%
16%
17%
11%
12%
12%
18%
18%
14%
14%
10%
7%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Godavari Drugs insights

68 extracted metrics + investor summaries across FY10–FY27.

Shareholding Pattern

DIIs2.79%Public42.96%Others14.02%Promot.40.23%As ofSep 2026
0.21% of promoter holding pledged as of 14 Oct 2026

Documents

Frequently Asked Questions about Godavari Drugs

What does Godavari Drugs Ltd do?
Incorporated in 1987, Godavari Drugs Ltd manufactures and sale of Active Pharmaceutical Ingredients and their intermediates[1]
Where is Godavari Drugs Ltd (GODAVARI) listed?
Godavari Drugs Ltd trades under code 530317 on the BSE.
Which sector does Godavari Drugs Ltd belong to?
Godavari Drugs Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Godavari Drugs Ltd?
Godavari Drugs Ltd has a market capitalisation of ₹132.06 Cr as of 28 Oct 2026, which places it in the Small Cap band.
What is the PE ratio of Godavari Drugs Ltd?
Godavari Drugs Ltd trades at a PE ratio of 25.69 as of 28 Oct 2026, on earnings per share of ₹4.71, against a book value of ₹71.05 per share.
What is the 52-week high and low of Godavari Drugs Ltd?
Over the last 52 weeks Godavari Drugs Ltd has traded between ₹69.7 and ₹144.35 as of 28 Oct 2026.
What is the Return on Equity (ROE) of Godavari Drugs Ltd?
Godavari Drugs Ltd reported a return on equity of 5.39%. Its debt-to-equity ratio is 1.08.

Company Information

Incorporated in 1987, Godavari Drugs Ltd manufactures and sale of Active Pharmaceutical Ingredients and their intermediates[1]

Website godavaridrugs.com
Face Value ₹ 10
Shares Outstanding 1,09,14,309

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/530317.md for Godavari Drugs Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month